Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
January 1, 0001
-
26 min
7 Key Takeaways
-
1
Multiple myeloma accounts for 1% of malignancies and has rising incidence.
-
2
Average age of diagnosis is 69 years.
-
3
Proteasome inhibitors and immunomodulatory agents improve survival.
-
4
Clinical trial outcomes emphasize the importance of deep responses.
-
5
Safety and efficacy profiles vary among novel agents.
-
6
Thromboembolic events are a significant risk requiring prophylaxis.
-
7
Guidelines from NCCN and expert consensus groups assist in treatment planning.
Multiple myeloma (MM) is the second most common hematologic malignancy, with around 21,700 new cases annually in the U.S. Although incurable, recent advancements in treatment have led to improved survival rates. Novel agents like proteasome inhibitors and immunomodulatory drugs are enhancing outcomes by targeting tumor biology and the microenvironment. Clinical trials have underscored the importance of deep responses for long-term survival, necessitating familiarity with treatment guidelines and the management of treatment-related toxicities.
Listen Tab content
